AstraZeneca PLC (JOBS) May Join Rush to Develop Generic Biological Drugs

December 23, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Dec. 23 (Bloomberg) -- AstraZeneca Plc is looking to widen its share of the $94 billion market for biotechnology drugs by developing generic versions of those therapies, following U.S. rivals Merck & Co. and Eli Lilly & Co.

Twitter
LinkedIn
Facebook
Email
Print

AstraZeneca Pharmaceuticals LP